Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Caveolin 3 (CAV3) Peptide

CAV3 Reactivity: Human Host: Synthetic BP, IHC, WB
Catalog No. ABIN974490
  • Target See all Caveolin 3 (CAV3) products
    Caveolin 3 (CAV3)
    Origin
    Human
    Source
    • 2
    Synthetic
    Application
    Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
    Characteristics
    This is a synthetic peptide designed for use in combination with anti-CAV3 antibody (Catalog #: AVARP09021_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
    Purification
    Purified
  • Application Notes
    Each Investigator should determine their own optimal working dilution for specific applications.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
    Concentration
    1 mg/mL
    Buffer
    Final peptide concentration is 1 mg/mL in PBS.
    Handling Advice
    Avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target
    Caveolin 3 (CAV3)
    Synonyms
    LGMD1C Peptide, LQT9 Peptide, VIP-21 Peptide, VIP21 Peptide, AI385751 Peptide, Cav-3 Peptide, M-cav Peptide, caveolin-3 Peptide, im:6902906 Peptide, zgc:109710 Peptide, LOC733765 Peptide, CAV3 Peptide, cav3 Peptide, caveolin 3 Peptide, caveolin-3 Peptide, CAV3 Peptide, Cav3 Peptide, cav3 Peptide, LOC733765 Peptide, cav-3 Peptide
    Background
    CAV3 is a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites.

    Alias Symbols: LQT9, VIP21, LGMD1C, VIP-21

    Protein Interaction Partner: DAG1,DYSF,EGFR,GNAS,INSR,JPH2,NOS1,PFKM,SLC22A11,SLC8A1,DAG1,DYSF,EGFR,JPH2,PDGFRA,PDGFRB,PFKM,SLC8A1

    Protein Size: 151
    Molecular Weight
    17 kDa
    Gene ID
    859
    NCBI Accession
    NM_001234, NP_001225
    UniProt
    P56539
You are here:
Support